NeuroBo Pharma rises as obesity drug meets main goal in early-stage study

MetaVia

30/09/2024 13:34

** Shares of drug developer NeuroBo Pharmaceuticals  NRBO.O 
rise 3.3% to $3.43 premarket 
    ** Co says its obesity drug was found to be safe and well
tolerated and did not result in any serious adverse effects in
an early-stage study conducted with 45 obese, otherwise healthy
individuals
    ** The main goal of the study was to assess the safety and
tolerability of the drug by monitoring adverse events
    ** Five subjects receiving the treatment reported adverse
events vs 3 subjects in the placebo group - NRBO says
    ** As of last close, stock down 10.2% YTD

 (Reporting by Kashish Tandon in Bengaluru)
 ((Kashish.tandon@thomsonreuters.com))